Procore’s assets include a set of proprietary growth factors with enhanced activity, selectivity and stability.
The Fibroblast Growth Factor (FGF) family is one of the most versatile growth factor systems in the human body. FGF ligands and their cognate receptors play major roles in various signaling networks and cellular pathways that underlie processes such as angiogenesis (blood vessel formation), wound healing and tissue repair and regeneration.
However, therapeutic and industrial uses of FGF are limited. This is due mainly to the complexity of the FGF system and the lack of adequate screening and analytical tools that can relate a specific cellular function to specific FGF signaling molecules.
Prof. Avner Yayon, ProCore’s founder, a world-renowned expert in the FGF field, has developed a platform of novel FGF variants and FGF-related technologies.This platform consists of both valuable research tools and products that can potentially be used in clinical and diagnostic applications. These include the following:
- A set of FGF variants with distinct receptor selectivity and enhanced activity.
- Proprietary production protocols allowing the production of these novel growth factor variants as high grade and pure materials for research and clinical applications.
- A variety of novel analytical and functional assays for FGF and FGF receptors and their signaling pathways. These include both cell-free and cell-based assays enabling low to High Throughput Screening (HTS), for both agonists and antagonists of the FGF system.